SCHEMBL21296983

SCHEMBL21296983

CC(C)c1ccc(Oc2[nH]nnc2C(=O)O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 9/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 2/20 0.37
POLB P06746 2/20 0.37
MAPT P10636 2/20 0.37
NPC1 O15118 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
COPS5 Q92905 1/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23319926 0.96 HAO1 (0.39) HAO1RXRARXRBKDM4EMAPK1
SCHEMBL25463456 0.87 ACACB (0.41) HAO1RAB9AMAPTNPC1MEN1
SCHEMBL21296877 0.85 HAO1 (0.39) HAO1ALDH1A1
SCHEMBL21296897 0.84 HAO1 (0.41) HAO1RAB9ANPC1MEN1KMT2A
SCHEMBL24154727 0.84 RXRA (0.52) HAO1RXRARXRBGAA
SCHEMBL24154725 0.84 RXRA (0.44) HAO1RXRARXRB
SCHEMBL21296931 0.84 PTGS1 (0.45) HAO1RXRARXRBKDM4EMEN1
SCHEMBL29799243 0.84 PTGS1 (0.45) HAO1RXRARXRBKDM4EMEN1
SCHEMBL21296956 0.84 HAO1 (0.52) HAO1
SCHEMBL21296890 0.84 HAO1 (0.52) HAO1KDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX HAO1 14/4885RXRA 1818/4885RXRB 1742/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX HAO1 14/4885RXRA 1818/4885RXRB 1742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.